Sign in

Michael Riskin

Research Analyst at Bank of America

Michael Riskin is a seasoned financial professional specializing in financial planning and practice management, with more than 15 years of industry experience. He is recognized for his expertise in advising clients and optimizing financial strategies, primarily within CPS, though specific coverage of companies and quantitative performance metrics are not publicly available. Riskin has established a comprehensive career in financial services, demonstrating a lifelong commitment to the field, but details regarding his tenure at Bank of America, prior firms, or definitive start dates remain undisclosed. Information on professional credentials such as FINRA registration or securities licenses is currently unavailable.

Michael Riskin's questions to LABCORP HOLDINGS (LH) leadership

Question · Q3 2025

Michael Riskin from Bank of America (question asked by Aaron) inquired about the double-digit growth in esoteric testing compared to routine tests, how Labcorp prioritizes R&D investments in this area, and the commercialization strategy and reimbursement updates for Genoscopy's ColoSense.

Answer

Chairman and CEO Adam Schechter confirmed strong esoteric growth, emphasizing its importance for comprehensive patient care despite lower volume. He stated Labcorp focuses R&D on high-growth areas like oncology, women's health, neurology, and autoimmune diseases, aiming for 2-3x market growth. Labcorp is agnostic to internal development versus licensing/acquiring tests to bring the best solutions to market quickly.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts